

U-shaped association between plasma sphingosine-1-phosphate levels and mortality in patients with chronic systolic heart failure: A prospective cohort study.

Yanbo Xue

First Affiliated Hospital of Xi'an Jiaotong University <https://orcid.org/0000-0003-0845-048X>

Jiang Wei

The second affiliated hospital of air force medical university

Ma Qiong

First affiliated hospital of Xi'an Jiaotong University

Wang Xiqiang

First Affiliated Hospital of Xi'an Jiaotong University

Jia Pu

Northwest University

Li Qiang

Xi'an Jiaotong University

Chen Shuping

First Affiliated Hospital of Xi'an Jiaotong University

Song Bingxue

The affiliated hospital of Qingdao University

Wang Ya

First Affiliated Hospital of Xi'an Jiaotong University

Zhang Jingwen

Sun Yat-sen University First Affiliated Hospital

Liu Jing

First Affiliated Hospital of Xi'an Jiaotong University

Yang Guodong

First Affiliated Hospital of Xi'an Jiaotong University

Lin Yuyao

First Affiliated Hospital of Xi'an Jiaotong University

Liu Jing

First Affiliated Hospital of Xi'an Jiaotong University

Wei Linyan

First Affiliated Hospital of Xi'an Jiaotong University

Dong Caijuan

First Affiliated Hospital of Xi'an Jiaotong University

Li Haiquan

First Affiliated Hospital of Xi'an Jiaotong University

Xie Zhonglei

First Affiliated Hospital of Xi'an Jiaotong University

Bai Ling

First Affiliated Hospital of Xi'an Jiaotong University

Aiqun Ma (✉ aiqun.ma@xjtu.edu.cn)

First Affiliated Hospital of Xi'an Jiaotong University <https://orcid.org/0000-0002-8589-7915>

Research

Keywords: Heart failure, Sphingosine-1-phosphate, All-cause mortality, Prognosis

Posted Date: December 30th, 2019

DOI: <https://doi.org/10.21203/rs.2.19570/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at Lipids in Health and Disease on June 4th, 2020. See the published version at <https://doi.org/10.1186/s12944-020-01262-2>.

Abstract

Background: The endogenous lipid molecule sphingosine-1-phosphate (S1P) has received attention in the cardiovascular field due to its significant cardioprotective effects, as revealed in animal studies. The purpose of our study was to identify the distribution characteristics of S1P in systolic heart failure patients and the prognostic value of S1P for long-term prognosis.

Methods: We recruited 210 chronic systolic heart failure patients from June 2014 to December 2015. Meanwhile 54 healthy people in the same area were selected as controls. Plasma S1P was measured by liquid chromatography-tandem mass spectrometry. Patients were grouped according to the baseline S1P level quartiles, and restricted cubic spline plots described the association between S1P and all cause death. Cox proportional hazard analysis was used to determine the relationship between category of S1P and all-cause death.

Results: Compared with the control group, the plasma S1P in chronic heart failure patients demonstrated a higher mean level (1.269 $\mu\text{mol/L}$ vs 1.122 $\mu\text{mol/L}$, $P=0.006$) and a larger standard deviation (0.441 vs 0.316, $P=0.022$). After a follow-up period of 31.7 ± 10.3 months, the second quartile (0.967-1.192 $\mu\text{mol/L}$) with largely normal S1P levels had the lowest all-cause mortality and either an increase (HR=3.87, 95%CI 1.504-9.960, $P=0.005$) or a decrease (HR=3.271, 95%CI 1.277-8.381, $P=0.014$) predicted a worse prognosis. Being grouped into the quartile4 group after correction of other variables with prognostic values for all-cause mortality (adjusted HR=3.685 [1.391-9.763], $p=0.009$) still predicted a worse prognosis. The survival curves showed that S1P levels in the quartile1 and quartile4 groups significantly reduced the patient survival rate.

Conclusions: Plasma S1P levels in systolic heart failure patients are related to the long-term all-cause mortality with a U-shaped correlation.

1 Introduction

Heart failure is the terminal state of a variety of cardiovascular diseases that affects the health of patients and increases the burden on society. Despite formal drug treatments, the 5-year mortality of heart failure patients remains high [1, 2]. Searches for new biomarkers with long-term prediction value and early identification for high-risk patients to reduce mortality are always important for guiding clinical treatments. Heart failure activates a variety of systemic compensatory stress responses, including stimulation of the sympathetic catecholamine system, the renin angiotensin aldosterone system and other systems. In recent years, a large number of studies have found that immune system activation and dysfunction are present during the occurrence and development of heart failure, and these immunity disorders always occur simultaneously with abnormalities of the neurohumoral endocrine system. Therefore, in-depth investigations of these pathophysiological changes call for appropriate molecules to connect the two systems together.

The circulating immunoregulatory factor sphingosine-1-phosphate (S1P), an endogenous lipid molecule, is produced by the phosphorylation of sphingosine by sphingosine kinases. It is an intracellular secondary messenger and can also enter the circulation and bind to the G protein-coupled receptor family of sphingosine-1-phosphate receptors 1–5 to play an immunomodulatory role [3, 4]. In recent years, studies have shown that S1P interacts with β -adrenergic receptors to play a role in simultaneously regulating immune system and sympathetic nervous system functions [5, 6]. Meanwhile, S1P has received attention due to its important role in cardiac ischaemia-reperfusion injury [7, 8] and ventricular remodelling inhibition [9, 10]. It is interesting that previous in vitro and in vivo studies of S1P levels and its receptor targeting activities have a common feature that whether the S1P level is elevated or depressed in the experimental group, the heart-protecting effect is always achieved through adjusting the S1P/S1PR axis function to the level of the normal control group. These results suggest that keeping S1P levels in the normal range may have protective effects on the heart [11, 12].

Until now, it has been unclear whether there are abnormal S1P levels in clinical patients with chronic heart failure (CHF), what its normal level is, what its clinical significance is, and whether it is related to poor prognosis. The purpose of our study was to identify the distribution characteristics of S1P levels in the blood circulation of outpatients with stable systolic heart failure and its prognostic value for long-term prognosis.

2 Methods

2.1 Patient selection

We recruited systolic heart failure patients treated in Jingyang Hospital and Xunyi Hospital, both located in Shaanxi Province, and who were diagnosed according to the “2014 China Heart Failure Diagnosis and Treatment Guideline” and “2012 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure” [13] before and treated in the outpatient clinic from June 2014 to December 2015. The inclusion criteria were the following standards: 1. 18 to 80 years of age; 2. Echocardiography showing left ventricular systolic dysfunction ($EF \leq 50\%$); 3. Not hospitalized in the past month; 4. Standardized drug treatment regimens. Patients were excluded if they met any of the following: 1. systolic blood pressure < 90 mmHg or haemodynamic instability; 2. second-degree type II AV block or severer; 3. HR < 55 beats/min in conscious resting state; 4. significant abnormal liver or kidney function; 5. malignancy; 6. pregnant or lactating women; 7. dementia or mental disorder. The study design and population are detailed in Fig. 1.

All participants signed written informed consent forms. The study conformed to the principles outlined in the Declaration of Helsinki and was approved by relevant ethical bodies. Registration site:

<http://www.chictr.org.cn>. Registration number: ChiCTR-ONC-14004463.

2.2 Procedural management

A group of senior professors from the First Affiliated Hospital of Xi'an Jiaotong University formed a coaching team to conduct unified and standardized training for the clinicians of the two hospitals

through centralized training and prescription instruction before patient enrolment, according to the guidelines [13] to ensure consistent treatment management principles to reduce deviations in patient treatment regimens arising from different medical units and physicians. The biomarker data generated in this prospective study were not used for treatment decisions.

On the day of enrolment, the patients were examined by uniformly trained physicians and systematically measured for body weight, blood pressure and heart rate. Heart failure symptoms were assessed using the New York Heart Association functional classification, and a 12-lead ECG was performed. Echocardiography was performed using Philips iE33 ultrasound system (Philips, Amsterdam, Netherlands) by experienced cardiologists independent of the 2 hospitals. The left ventricular ejection fraction (LVEF) value was uniformly measured by biplane Simpson rule. At last physicians recorded the treatment regimens.

2.3 Blood sample

Blood samples were obtained by venipuncture and centrifuged at 1700 g to separate EDTA plasma and serum at once and shipped to a central laboratory with standardized procedures. Serum was collected for analysis including liver, kidney and lipids function-related tests and electrolytes (HITACHI 7180, HITACHI, Tokyo, Japan). Full blood samples were used to test the hematologic parameters (KX 21N analyzers, Sysmex, Kobe, Japan). After these tests, all samples were stored at -80 °C for future analysis. The serum NT-proBNP levels were detected as a batch analysis in a central laboratory by electrochemiluminescence immunoassay (Roche Diagnostics, Rotkreuz, Switzerland).

Plasma S1P was measured by liquid chromatography-tandem mass spectrometry. We used a previously described protocol with minor modifications [14]. Plasma (100 µL) was deproteinated by the addition of methanol (400µL). The internal standard D-erythro-C17-sphingosine-1-phosphate (10µL, 10 µmol/L, Avanti Polar Lipids Inc. Alabaster, USA) with the m/z 366.4 to 250.4 was used to correct for variations in sample preparation and instrument response. Extracts were cleared by 5810R EPPENDORF centrifugation (12000 rpm, 10 min) (EPPENDORF, Wesseling-Berzdorf, Germany) and subjected to reverse-phase chromatography on an Agilent Eclipse XDB C-18 analytical column (2.1 mm × 150 mm, 3.5 µm) (Agilent Technologies Inc. Santa Clara, USA) at a flow rate of 0.3 ml/min. S1P was eluted by a ballistic gradient (30–85% methanol, 0.2% formic acid; % = volume%) and measured by a Shimadzu HPLC system coupled to an API 4000 tandem mass spectrometer (Applied Biosystems/MDS SCIEX, Framingham, USA). The quantification determination was performed using multiple reaction monitoring with the m/z 366.4 to 250.4 (M + H S1P parent ion). A calibration curve (0.125-5 µmol/L S1P) was generated to calculate S1P level in samples. The same sample was tested multiple times with a relative standard deviation less than 5% within 12 hours, and less than 10% within 6 days when stored at room temperature.

2.4 Assessment of outcomes

The primary endpoints were all-cause mortality and hospitalization due to aggravation of heart failure. The occurrence of patient end point events was determined through telephone follow-ups of the patients and their families, a review of hospital medical records and death certificates. And we used the “average

No. of hospitalization per person per year” to adjust the multiple hospitalizations and different length of follow-up. The follow-up ended on December 31, 2017 or patient death.

2.5 Statistical analysis

The Kolmogorov-Smirnov test was used to test whether a variable conformed to a normal distribution. Normal distribution variables were expressed as the mean \pm standard deviation (SD), and Student’s T test was used for comparisons between groups. Variables that did not conform to a normal distribution were expressed as the median [interquartile 1, interquartile 3], and the Mann-Whitney U test was used for inter-group comparison. Patients were grouped according to the baseline S1P level quartiles (Quartile1 (Q1), Quartile2 (Q2), Quartile3 (Q3) and Quartile4 (Q4) group). The baseline characteristics among the 4 groups were analyzed by the Kruskal–Wallis test for nonparametric variables, ANOVA for parametric variables, and the χ^2 test for categorical variables. Spearman and Pearson correlation analyses were used to explore the correlations.

We analyzed S1P level as a continuous variable, fitting a restricted cubic spline function with 4 knots (located at the 5th, 35th, 65th, and 95th percentiles), and 1.10 $\mu\text{mol/L}$ (The median S1P level in control group.) was chosen as the reference for all spline plots [15].

Cox proportional hazard analysis was used to determine the relationship between category of S1P and all-cause death. The Q2 group was selected as the reference category because it has the largely normal S1P levels and associated with the lowest risk of all-cause mortality [16]. Univariable analysis was used for all baseline variables to find variables that might be associated with all-cause death. Next, all variables that showed a significant ($P < 0.10$) univariate association were included stepwise in a multivariable model. We used the “forward selection” to make sure that variables which not retained significance ($P > 0.10$) in this multivariable analysis were not added into the final model. The only missing data in the final model were 2 patients for NT-proBNP ($< 1\%$), and we replaced the two missing NT-proBNP by the previous nonmissing value. As a result, the final model contains all 210 observed patients, 50 events and no more than 5 variables which were identified to be independent predictors of all-cause death (At least 10 events were available for each prognostic factor tested).

Survival curves were using the Kaplan-Meier method and the log-rank test was used for comparison. A 2-tailed P value of less than 0.05 was considered statistically significant. SPSS22.0 (SPSS, Inc., Chicago, IL, USA), STATA13.1 (StataCorp, Inc., Texas, USA) and GraphPad prism 5.0 (GraphPad Software, Inc., Cary, NC) were used for statistical analysis and graphing.

3 Results

3.1 Baseline and distribution characteristics of S1P levels

Among the CHF patients who completed the follow-up, 210 patients had plasma S1P test results. The patients were grouped according to the baseline plasma S1P level quartiles, and 54 healthy volunteers in the same area were selected as controls. The comparison result of S1P level is shown in **Fig 2**. The

overall plasma S1P of CHF patients had a higher mean value (1.269 $\mu\text{mol/L}$ vs 1.122 $\mu\text{mol/L}$, $P=0.006$) and a larger standard deviation (0.441 vs 0.316, $P=0.022$) than the control group. Compared to the control group, the S1PQ1 was lower, the S1PQ3 and S1PQ4 were higher, and S1PQ2 showed no statistical difference.

The baseline data for the entire study population and the occurrence of outcomes in each quartile are presented in **Table 1**. The average age of the patients was 61.7 (SD 9.3) years, males accounted for 63.8%, the LVEF was 35.76 (SD 7.57) %, the NT-proBNP was 1633.5 [857.33-3123.25]pg/mL, 9.1% of patients had a history of diabetes, and 31.3% had a history of hypertension. Groups with higher S1P levels had a higher red blood cell count ($P<0.001$), haemoglobin ($P=0.018$), monocyte count ($P<0.001$) and percentage of monocytes ($P<0.001$). The neutrophil count ($P=0.001$) and percentage of neutrophils ($P=0.007$) showed the opposite trend. In ultrasonic cardiogram, LVEF% ($P=0.04$) and LVEDV ($P=0.039$) differed between the groups. Although we used the uniform principles, β -receptor blockers were used more frequently in the Q3 group, which might be related to the fewer contraindications for drug use. The usage rates of other drugs were not significantly different between the groups.

The correlation analysis showing that the plasma S1P level was positively correlated with the red blood cell count ($r=0.312$, $P<0.001$), haemoglobin ($r=0.189$, $P=0.006$), monocyte count ($r=0.287$, $P<0.001$) and monocyte percentage ($r=0.412$, $P<0.001$) and was negatively correlated with the percentage of neutrophils ($r=-0.263$, $P<0.001$).

3.2 Follow-up

After an average follow-up period of 31.7 (SD 10.3) months (range: 2–43 months), 50 all-cause deaths occurred in the 210 patients, and 121 patients were re-hospitalized due to exacerbation of heart failure (**Table 1**). The Q2 group had the lowest all-cause mortality and proportion ($n=6$, 11.3%), while Q3 ($n=12$, 22.6%), Q4 ($n=16$, 30.8%) and Q1 group ($n=16$, 30.8%) showed increased all-cause mortality. **Fig 3** shows the result of restricted cubic spline plots for all-cause mortality. And it also presents the distribution of plasma S1P levels of all enrolled CHF patients. Cubic spline plots revealed significance thresholds at 0.91 $\mu\text{mol/L}$ and 1.49 $\mu\text{mol/L}$. And the all-cause mortality demonstrated a U-shaped correlation with the S1P level, which was consistent with the results in **Fig 2**, where the S1P level of the Q2 group and the control group did not significantly differ.

The same trend could be found in all-cause mortality and hospitalization rates during the first two years of follow-up and the average No. of hospitalization per person per year. But there was no significant difference in the HF re-hospitalization rate between the groups.

3.3 Prognostic value of baseline S1P levels

The Cox proportional hazard analysis results are shown in **Table 2**. The patient plasma S1P level belonging to the Q1 group, the patient plasma S1P level belonging to the Q4 group, IgNT-proBNP, DBP, uric acid, haemoglobin, LVEF, LVEDD, LVESD, LVEDV and LVESV were found to be univariate predictors of all-

cause death. Multivariable analysis showed that IgNT-proBNP (HR: 4.650; 95%CI: 2.172-9.953; $P<0.001$), DBP (HR: 0.971; 95%CI: 0.948-0.996; $P=0.022$), LVEDV (HR: 1.004; 95%CI: 1.000-1.008; $P=0.039$) and patient plasma S1P level belonging to the Q4 group (HR 3.134; 95%CI 1.211-8.111; $P=0.019$) were independent predictors of all-cause mortality, while the prognostic value of patient plasma S1P level belonging to the Q1 group was diminished (HR: 1.901; 95%CI: 0.711-5.083; $P=0.200$).

To clarify the main factors responsible for the disappearance of the prognostic value of S1PQ1 in the multivariate regression analysis, we conducted in-depth investigations on the factors influencing the prognostic value of being grouped to the S1PQ1 and S1PQ4 groups on all-cause mortality (**Table 2**). The results showed that the predictive value of “Being grouped to the S1PQ1 group” subsided after additional adjustment for IgNT-proBNP and LVEDV (HR: 2.043; 95%CI: 0.771-5.413; $P=0.115$). “Being grouped to the S1PQ4 group” remained an independent predictor of outcome after adjustments for all of the above variables.

The survival curves in **Fig 4** show that plasma S1P levels in the Q1 and Q4 groups significantly reduced the patient survival rate. But there was no significant difference in the re-hospitalization rate due to aggravated heart failure between groups.

4 Discussion

The main finding of this study is that plasma S1P in patients with heart failure is associated with all-cause mortality, which shows a U-shaped correlation. And we also described the overall distribution of S1P levels in heart failure patients and first provided CHF patients normal (low risk) S1P thresholds for reference.

4.1 U-shaped relationship bridges the gap from basic study to clinic patients

In this study, we found that S1P had different distribution characteristics in the normal population and CHF patients. Abnormally increased (Q3, Q4 group), decreased (Q1 group) and roughly normal S1P levels (Q2 group) coexisted in CHF patients. Because of abnormal decrease had less amplitude and room than increase, the CHF group showed a higher mean value (1.269 $\mu\text{mol/L}$ vs 1.122 $\mu\text{mol/L}$, $P = 0.006$) and standard deviation (0.441 vs 0.316, $P = 0.022$) of S1P level than control group. Combined with the restricted cubic spline results, where patients with roughly normal S1P levels (Q2 group) had the lowest mortality rate, these results suggest that the S1P level is associated with all-cause mortality in a U-shaped relationship, indicating that there may be a normal value range for S1P levels in the middle of the entire distribution rather than on either side.

In previous animal model studies, different results were reported for the S1P/S1PR axis function. Zhang F et al. [17] showed that plasma S1P levels, Sphk1 and S1PR1 activities increased after myocardial infarction in rats and that downregulation of S1P function by an inhibitor might protect the heart. In

contrast, Yeh CC et al. [10] showed that S1P levels and Sphk activity decreased after myocardial infarction in rats and that administration of S1PR1 receptor agonists reduced apoptosis and ventricular remodelling after infarction. Hofmann U et al. [18] found that the S1P receptor agonist FTY720 could improve the ischaemia-reperfusion injury of rat cardiomyocytes. Santos-Gallego CG et al. [19] found that the use of FTY720 in the porcine ischaemia-reperfusion model improved ischaemia-induced left ventricular remodelling. Cannavo A et al. [5] showed that serum S1P levels and S1PR1 receptor expression decreased after myocardial infarction in rats, and exogenous S1P supplementation could inhibit apoptosis and fibrosis and improve ventricular remodelling after infarction. Yan H et al. [20] demonstrated that exogenous S1P improved rat cardiac hypertrophy induced in the transverse aortic constriction model. These studies used different animal models, observed different time points during the disease process, and identified different S1P change directions. But fortunately, the similarity of these studies is that either an increase or a decrease of S1P levels in heart failure animal models is harmful, and regulation of abnormal S1P level towards the control level is beneficial for heart protection. We identified both elevated and decreased S1P levels in clinical patients and a U-shaped association with all-cause deaths, allowing different directions of previous animal model studies to be simultaneously reproduced at the clinical level.

In summary, before this study, there was insufficient information to suggest that either upregulate or downregulate S1P signaling will be effective in the setting of heart failure [11]. For the first time, our study showed a U-shaped relationship between the S1P levels and all-cause death, and provided CHF patients normal (low risk) S1P thresholds for reference. Through restoring abnormal levels to a normal range instead of simply up regulation or down regulation, S1P has the potential to be a therapeutic target for reducing the risk of death in patients with heart failure in the future.

4.2 U-shaped relationship bridges the gap between different mechanisms

In this study, the prognostic value of decreased plasma S1P levels for all-cause mortality diminished after correction with NT-proBNP and LVEDV. The LVEDV is an independent risk factor for all-cause death and also presents the degree of left ventricular remodeling in heart failure. The S1PQ1 group had higher LVEDV than S1PQ2 group (230.46 (SD 83.55) vs 187.76 (SD 65.60), $P = 0.007$). And Cannavo A et al. [5] showed a mutual regulation mechanism between S1P/S1PR function and β -adrenergic receptor function. These results suggest that an abnormal decline of plasma S1P may be associated with heavier ventricular remodelling. Furthermore, Gazit SL et al. [21] showed that S1P deficiency may aggravate vasoplegia, arguing a vital role for S1P in maintaining vascular resistance during recovery from circulatory shock. The results may explain the relationship between the increased all-cause mortality and low S1P levels in some patients.

The prognostic value of an abnormal elevation of sphingosine-1-phosphate (S1P) for death is completely independent of the previous high-risk factors and the prediction indexes associated with heart failure. After adjusting for variables associated with S1P and risk factors for all-cause death in heart failure, the

prognostic value of S1P was not reduced, suggesting the presence of a new mechanism for the occurrence and development of heart failure that is independent of previously identified conventional risk factors. As an endogenous sphingolipid molecule with important biological activity, S1P has important immunomodulatory functions [22, 23] that S1P/S1PR abnormally changes in autoimmune diseases such as rheumatoid arthritis [24] and in severe infectious diseases such as sepsis [14]. The excessive activation of S1P/S1PR can also lead to the occurrence of immune disorders and inflammation [25] which is also mechanisms of heart failure. The cause of S1P changes in heart failure patients, the mechanism by which excessive activation of the S1P/S1PR axis leads to increased all-cause mortality in these patients, and the relationship between the S1P/S1PR axis and immune disorders await further research for confirmation.

We hypothesize that during the occurrence and development of heart failure, the two different directions of abnormal changes in plasma S1P levels are linked to the two different mechanisms of ventricular remodelling and immune disorders, separately or simultaneously. S1P may have the potential to act as the "bridge molecule" that links the neurohumoral endocrine system and the immune system, which can be investigated in future studies on the pathophysiological process of heart failure occurrence and development.

4.3 Limitations

There are several limitations related to our study. Because out-of-hospital CHF patients were enrolled in this study, some patients did not undergo coronary angiography, in these cases the patients were not classified according to the aetiology of heart failure. As a result, whether different causes could affect the direction of plasma S1P could not be analysed in depth. Furthermore, we don't know the variance of S1P value if it is measured at different time points in the same patient at present. Although the all-cause mortality during the whole follow-up period and in the first two-year showed the same trend, we still wonder if it's more appropriate to use the sequential value of S1P to predict the prognosis more than 2 years after the enrolment. Moreover, only patients with heart failure in 2 hospitals were enrolled in this study. Due to these limitations, we consider our study mainly as hypothesis generating. Future large-scale, multicentre clinical research will effectively improve the reliability of these findings.

5 Conclusions

In patients with chronic systolic heart failure, plasma S1P levels are related to the long-term all-cause mortality with a U-shaped correlation. Through restoring abnormal levels to a normal range instead of simply up regulation or down regulation, S1P may have the potential to be a therapeutic target for reducing the risk of death in patients with heart failure in the future.

Abbreviations

AV block

Atrioventricular block

ACEI
Angiotensin-converting enzyme inhibitor
ARB
Angiotensin II receptor blocker
CHF
Chronic heart failure
DBP
Diastolic blood pressure
ECG
Electrocardiograph
EDTA
Ethylene diamine tetraacetic acid
EF
Ejection fraction
eGFR
Estimated glomerular filtration rate
HDL
High-density lipoprotein
HR
Hazard ratio
LDL
Low density lipoprotein
LV
Left ventricle
LVEF
Left ventricular ejection fraction
LVEDD
Left ventricular end-diastolic dimension
LVESD
Left ventricular end-systolic dimension
LVEDV
Left ventricular end-diastolic volume
LVESV
Left ventricular end-systolic volume
LY
Leukomonocyte
MONO
Monocyte
NEUT
Neutrophil

NT-proBNP
N-terminal pro B-type natriuretic peptide
NYHA
New York Heart Association
S1P
Sphingosine-1-phosphate
S1PR
Sphingosine-1-phosphate receptor
SBP
Systolic blood pressure
SD
Standard deviation

Declarations

Ethics approval and consent to participate

Ethical approval was obtained from the ethics committee of the First Affiliated hospital of Xi'an Jiaotong University (2013-133). All patients and controls provided written informed consent. All steps of the study conformed to the Helsinki Declaration and Good Clinical Practice guidelines.

Consent for publication

Not applicable.

Availability of data and materials

The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by the Ministry of Science and Technology and the Ministry of Finance of the People's Republic of China. [Grant numbers: No.2012GS610101 and No. 2017YFC1308302]

Authors' contributions

XY conducted experiments, performed statistical evaluations, and wrote the manuscript. JW provided methodology and formal analysis. JP provided methodology. LQ performed statistical evaluations. MQ, WX, WY, ZJ, LJ, LY, LJ, WL, DC, LH, XZ obtained samples from patients, recorded patient history, assessed

the clinical characteristics of patients and performed interviews during the enrolment process. CS, SB supervised sample collection. BL provided feedback on the manuscript and funding acquisition. MA conceived the idea, designed the study, obtained necessary permissions, provided scientific support and funding acquisition.

Acknowledgements

Not applicable

References

- [1] Ponikowski P, Voors AA, Anker SD, et al. 2016 esc guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the european society of cardiology (esc). Developed with the special contribution of the heart failure association (hfa) of the esc. *Eur Heart J*. 2016;37(27):2129-2200.
- [2] Benjamin Ej, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: A report from the american heart association. *Circulation*. 2019;139(10):e56-e528.
- [3] Spiegel S, Milstien S. The outs and the ins of sphingosine-1-phosphate in immunity. *Nat Rev Immunol*. 2011;11(6):403-415.
- [4] Takabe K, Paugh Sw, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: Therapeutic targets. *Pharmacol Rev*. 2008;60(2):181-195.
- [5] Cannavo A, Rengo G, Liccardo D, et al. Beta1-blockade prevents post-ischemic myocardial decompensation via beta3ar-dependent protective sphingosine-1 phosphate signaling. *J Am Coll Cardiol*. 2017;70(2):182-192.
- [6] Cannavo A, Rengo G, Liccardo D, et al. Beta1-adrenergic receptor and sphingosine-1-phosphate receptor 1 (s1pr1) reciprocal downregulation influences cardiac hypertrophic response and progression to heart failure: Protective role of s1pr1 cardiac gene therapy. *Circulation*. 2013;128(15):1612-1622.
- [7] Theilmeyer G, Schmidt C, Herrmann J, et al. High-density lipoproteins and their constituent, sphingosine-1-phosphate, directly protect the heart against ischemia/reperfusion injury in vivo via the s1p3 lysophospholipid receptor. *Circulation*. 2006;114(13):1403-1409.
- [8] Otaka N, Shibata R, Ohashi K, et al. Myonectin is an exercise-induced myokine that protects the heart from ischemia-reperfusion injury. *Circ Res*. 2018;123(12):1326-1338.
- [9] Takuwa N, Ohkura S, Takashima S, et al. S1p3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. *Cardiovasc Res*. 2010;85(3):484-493.

- [10] Yeh CC, Li H, Malhotra D, Huang Mc, et al. Sphingolipid signaling and treatment during remodeling of the uninfarcted ventricular wall after myocardial infarction. [Am J Physiol Heart Circ Physiol](#). 2009;296(4):H1193-1199.
- [11] Mann DL. Sphingosine 1-phosphate as a therapeutic target in heart failure: More questions than answers. [Circulation](#). 2012;125(22):2692-2694.
- [12] Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in the heart: A decade of progress. [Biochim Biophys Acta](#). 2013;1831(1):203-212.
- [13] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. [Eur Heart J](#) 2012;33(14):1787-1847.
- [14] Winkler MS, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. [Crit Care](#). 2015;19:372. doi: [10.1186/s13054-015-1089-0](#).
- [15] Harrell F. Regression Modelling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York, NY: SpringerVerlag; 2001.
- [16] O'Donnell MJ, Yusuf S, Mente A, et al. Urinary Sodium and Potassium Excretion and Risk of Cardiovascular Event. [JAMA](#).2011;306(20):2229-2238.
- [17] Zhang F, Xia Y, Yan W, et al. Sphingosine 1-phosphate signaling contributes to cardiac inflammation, dysfunction, and remodeling following myocardial infarction. [Am J Physiol Heart Circ Physiol](#). 2016;310(2):H250-261.
- [18] Hofmann U, Burkard N, Vogt C, et al. Protective effects of sphingosine-1-phosphate receptor agonist treatment after myocardial ischaemia-reperfusion. [Cardiovasc Res](#). 2009;83(2):285-293.
- [19] Santos-Gallego CG, Vahl TP, Goliash G, et al. Sphingosine-1-phosphate receptor agonist fingolimod increases myocardial salvage and decreases adverse postinfarction left ventricular remodeling in a porcine model of ischemia/reperfusion. [Circulation](#). 2016;133(10):954-966.
- [20] Yan H, Yi S, Zhuang H, Wu L, Wang DW, Jiang J. Sphingosine-1-phosphate ameliorates the cardiac hypertrophic response through inhibiting the activity of histone deacetylase-2. [Int J Mol Med](#). 2018;41(3):1704-1714.
- [21] Gazit SL, Mariko B, Thérond P, et al. Platelet and Erythrocyte Sources of S1P Are Redundant for Vascular Development and Homeostasis, but Both Rendered Essential After Plasma S1P Depletion in Anaphylactic Shock. [Circ Res](#) 2016;119(8):e110-126

- [22] Yanagida K, Hla T. Vascular and immunobiology of the circulatory sphingosine 1-phosphate gradient. [Annu Rev Physiol](#). 2017;79:67-91.
- [23] Rosen H, Stevens Rc, Hanson M, Roberts E, Oldstone MB. Sphingosine-1-phosphate and its receptors: Structure, signaling, and influence. [Annu Rev Biochem](#). 2013;82:637-662.
- [24] Choi HS, Kim KHA-Ohoo, Jin S, et al. Decreased expression of sphingosine-1-phosphate receptor 1 in the blood leukocyte of rheumatoid arthritis patients. [Immune Netw](#). 2018;18(5):e39, doi: 10.4110/in.2018.18.e39.
- [25] Liang J, Nagahashi M, Kim Ey, et al. Sphingosine-1-phosphate links persistent stat3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. [Cancer Cell](#). 2013;23(1):107-120.

Tables

Table 1 Baseline characteristics of the study population

	Control group n=54	All, n=210	S1P quartiles (n=210)			P-value	
			Q1<0.967µmol/L n=52	Q2(0.967-1.192µm l/L) n=53	Q3(1.200-1.490µm l/L) n=53		Q4 >1.490µmol/L n=52
Demographic characteristic							
Age, years	56.3±7.8	61.7±9.32	62.23±9.48	62.23±7.87	60.13±9.44	62.54±10.41	0.559
Sex, male n (%)	20(37.0%)	134(63.8)	37(71.2)	33(62.3)	28(52.8)	38(73.1)	0.195
Measurements at baseline							
Body mass index, kg/m ²	24.92±3.38	23.1±3.91	22.74±3.48	22.66±3.26	23.98±4.45	23.02±3.91	0.276
SBP, mmHg	125.89±17.57	121.73±21.32	122.33±19.96	122.3±20.99	117.92±17.95	124.67±26.07	0.446
DBP, mmHg	78.89±9.34	76.26±11.65	76.25±11.69	77.06±10.62	75.74±11.62	75.96±12.97	0.944
Heart rate, beats/min	67.0[63.5-72.5]	74.0[67.0-85.0]	70.5[64.3-83.8]	73.00[65.5-82.0]	76[70.0-90.5]	74[66.5-86.75]	0.127
NYHA class,							
I, n(%)	-	39(18.6)	11(21.2)	8(15.1)	12(22.6)	8(15.4)	0.579
II, n(%)	-	120(57.1)	27(51.9)	32(60.4)	26(49.1)	35(67.3)	
III, n(%)	-	51(24.3)	14(26.9)	13(24.5)	15(28.3)	9(17.3)	
eGFR,ml/min/1.73 m ²	120.27±17.94	87.29±20.55	90.97±19.24	84.33±21.22	84.18±19.89	89.98±21.39	0.194
Uric acid, µmol/L	255±53.36	328.1±89.92	304.53±100.80	327.36±87.59	339.73±86.53	340.33±81.85	0.148
Triglyceride, mmol/L	-	1.70±1.40	1.51±1.12	1.74±1.33	1.70±0.96	1.80±1.12	0.943
HDL, mmol/L	-	1.16±0.33	1.13±0.26	1.10±0.31	1.16±0.34	1.24±0.37	0.341
LDL, mmol/L	-	2.39±0.74	2.40±0.69	2.08±0.77	2.72±0.67	2.34±0.72	0.003
Erythrocyte,10 ¹² /L	-	4.59±0.91	4.40±0.55	4.43±0.57	4.62±0.66	4.92±0.91	<0.001
Hemoglobin, mmol/L	-	146.71±22.95	142.09±17.08	141.29±20.20	152.23±20.41	151.11±30.29	0.018
Platelet,10 ⁹ /L	-	167.5±63.0	169.7±75.0	152.5±55.1	179.1±55.5	168.8±63.5	0.182
Leukocyte,10 ⁹ /L	-	5.30[4.50-6.20]	5.10[4.40-6.00]	5.30[4.75-6.75]	6.20[5.05-7.85]	5.1[4.23-5.60]	<0.001

LY10 ⁹ /L	-	1.60[1.30-2.10]	1.50[1.25-2.05]	1.60[1.20-1.90]	1.77[1.50-2.20]	1.50[1.23-1.89]	0.019
LY%	-	30.71±8.90	31.25±9.18	29.37±9.96	30.32±7.66	32.04±8.66	0.469
MONO, 10 ⁹ /L	-	0.30[0.20-0.43]	0.19[0.11-0.32]	0.31[0.19-0.47]	0.36[0.30-0.50]	0.32[0.235-0.395]	<0.001
MONO%	-	5.70[4.00-7.10]	3.35[2.35-5.75]	5.85[3.80-6.65]	6.15[5.00-7.50]	6.6[5.4-7.7]	<0.001
NEUT10 ⁹ /L	-	3.10[2.38-3.80]	3.1[2.50-3.80]	3.30[2.34-4.30]	3.6[2.8-4.8]	2.7[2.2-3.3]	0.001
NEUT%	-	58.93±10.56	60.94±9.61	60.23±10.61	59.84±8.88	54.24±12.06	0.007
Echocardiography							
LVEF,%	-	35.76±7.57	35.05±8.75	37.25±6.56	33.66±7.14	37.11±7.30	0.04
LVEDD, mm	-	69.25±8.86	70.29±9.66	67.98±8.11	69.96±10.10	68.79±7.35	0.518
LVESD, mm	-	56.68±9.12	57.87±10.02	55.15±8.10	57.6±10.48	56.12±7.55	0.377
LVEDV, mL/m ²	-	210.01±76.12	230.46±83.55	187.76±65.60	213.87±82.17	207.46±58.74	0.039
LVESV, mL/m ²	-	143.56±61.05	154.98±69.41	124.73±51.84	147.23±65.35	146.87±52.98	0.07
Biomarkers							
S1P, μmol/L	1.100	1.196	0.806	1.08	1.350	1.779	<0.001
	[0.917-1.325]	[0.966-1.493]	[0.675-0.911]	[1.00-1.16]	[1.265-1.420]	[1.570-2.135]	
NT-proBNP, pg/mL	42.1	1633.5	2155	1465	1462	1620.5	0.416
	[35.5-56.5]	[857.3-3123.3]	[1093-3615]	[716-3254]	[778-2657]	[634.5-2890.5]	
Cardiac medication, n (%)							
ACEI/ARBs	-	185[88.1]	45[86.5]	46[86.8]	50[94.3]	44[84.6]	0.427
Beta blocker	-	169[80.5]	38[73.1]	41[77.4]	51[96.2]	39[75.0]	0.009
Diuretics	-	118[56.2]	29[55.8]	28[52.8]	32[60.4]	29[55.8]	0.89
Aldosterone receptor antagonist	-	162[77.1]	44[84.6]	36[67.9]	40[75.5]	42[80.8]	0.197

Outcomes

All-cause mortality, n (%)	-	50(23.8)	16(30.8)	6(11.3)	12(22.6)	16(30.8)	0.05
HF hospitalization, n (%)	-	121(57.6)	32(61.5)	27(50.9)	33(62.3)	29(55.8)	0.607
All-cause mortality in the first two-year, n (%)	-	30(14.3)	9(17.3)	3(5.7)	5(9.4)	13(25.0)	0.023
HF hospitalization in the first two-year, n (%)	-	100(47.6)	28(53.8)	20(37.7)	24(45.3)	28(53.8)	0.283
Average length of follow-up, year ^b	-	2.64±0.86	2.57±0.87	2.93±0.73	2.82±0.84	2.24±0.84	<0.001
Average No. of hospitalization per person per year ^c	-	0.68[0.53-0.82]	0.79[0.45-1.12]	0.46[0.19-0.74]	0.44[0.28-0.60]	0.82[0.45-1.20]	0.307

Continuous, normally distributed variables are reported as the mean ± SD, otherwise as the median [IQR] or n (%). ^aThe baseline characteristics among the 4 quartile groups were analyzed by the Kruskal–Wallis test for nonparametric variables, ANOVA for parametric variables, and the χ^2 test for categorical variables. ^bBecause of the lowest all-cause mortality rate, more patients in the S1PQ2 group could reach the end of the follow-up (December 31, 2017). So that S1PQ2 group had the longest average length of follow-up. ^c“Average No. of hospitalization per person per year” was used to adjust the multiple hospitalizations and different length of follow-up. Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; DBP, Diastolic blood pressure; eGFR, estimated glomerular filtration rate; NYHA, New York Heart Association; HDL, high-density lipoprotein; LDL, low density lipoprotein; LY, leukomonocyte; LV, left ventricle; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; MONO, monocyte; NT-proBNP, N-terminal pro B-type natriuretic peptide; NEUT, neutrophil; S1P, sphingosine-1-phosphate; SBP, Systolic blood pressure;

Table 2 Cox Regression Analysis for S1P and all-cause death

Model	HR ratio(95%CI) for S1PQ1	<i>P</i> -value	HR ratio(95%CI) for S1PQ4	<i>P</i> -value
S1P Crude HR	3.271(1.277-8.381)	0.014	3.870(1.504-9.960)	0.005
Model 1 S1P+related variables for S1P	3.197(1.237-8.264)	0.016	4.468(1.731-11.533)	0.002
Adjustments for predictors of all-cause death in CHF				
S1P+lgNT-proBNP	2.634(1.019-6.808)	0.046	3.504(1.362-9.017)	0.009
S1P+DBP	3.197(1.248-8.188)	0.015	3.984(1.546-10.265)	0.004
S1P+LVEF%	2.785(1.072-7.235)	0.036	3.742(1.453-9.637)	0.006
S1P+LVEDD	2.922(1.131-7.546)	0.027	3.723(1.447-9.578)	0.006
S1P+LVESD	2.850(1.101-7.378)	0.031	3.701(1.438-9.526)	0.007
S1P+LVEDV	2.689(1.032-7.007)	0.043	3.504(1.360-9.030)	0.009
S1P+LVESV	2.759(1.063-7.164)	0.037	3.415(1.321-8.825)	0.011
Adjustments for independent predictors of all-cause death in CHF				
S1P+lgNT-proBNP+LVEDV	2.043(0.771-5.413)	0.115	3.144(1.220-8.101)	0.018
S1P+lgNT-proBNP+DBP	2.420(0.932-6.281)	0.069	3.342(1.291-8.655)	0.013
S1P+LVEDV+DBP	2.574(0.981-6.750)	0.055	3.736(1.449-9.630)	0.006
Model 2 S1P+all independent predictors	1.901(0.711-5.083)	0.200	3.134(1.211-8.111)	0.019
Model 3 S1P+all predictors+medication	1.968(0.714-5.425)	0.190	2.082(1.345-9.376)	0.010

In the S1P Cox regression analysis model, we first selected the variables related to S1P in the correlation analysis. Model 1 is the model obtained after correcting all of related variables for S1P including UA, red blood cell count, monocyte count, percentage of monocytes, neutrophil count, and percentage of neutrophils. Subsequently, we used variables associated with all-cause death identified by single-factor Cox regression analysis in addition to the aforementioned S1P-related variables to correct for S1P. Model 2 used variables that were independently correlated with all-cause mortality in the multifactor regression analysis to correct for S1P, including NT-proBNP, DBP and LVEDV. Models 3 were adjusted for age, sex, prior history of hypertension and diabetes mellitus, all of the above predictors and treatment allocation (ACEIs or ARBs, β -receptor blockers, diuretics, and aldosterone receptor antagonists.).

Figures




Figure 1

The study design and population.




Figure 2

Plasma S1P levels and quartile grouping. Patients were divided into 4 groups according to the quartiles of baseline plasma S1P levels, and the plasma S1P levels of 54 healthy volunteers in the same area were used as the control group. *indicates $P \leq 0.05$ in the Mann-Whitney U test when compared with the control group, and # indicates $P \leq 0.05$ in the Levene test when compared with the control group. The error line is standard deviation. Abbreviations: S1P, sphingosine-1-phosphate.






Figure 3

Plasma S1P levels distribution and the restricted cubic spline plots for Cox models. The median S1P level in control group ($1.10\mu\text{mol/L}$) was chosen as the reference for all spline plots. Cubic spline plots revealed significance thresholds at $0.91\mu\text{mol/L}$ and $1.49\mu\text{mol/L}$. Abbreviations: HR, hazard ratio; S1P, sphingosine-1-phosphate.



— First quartile — Second quartile — Third quartile — Forth quartile

Figure 4

Kaplan-Meier curves of all-cause mortality (a) and heart failure hospitalization (b). Abbreviations: S1P, sphingosine-1-phosphate.